Watch part one of our interview with Don Tracy from @Pharmaceutical Executive, where we explain how our Femaseed technology supports women facing infertility challenges. https://lnkd.in/eW7PnrKp #Femasys #Femaseed #infertility
Femasys Inc.’s Post
More Relevant Posts
-
Watch part one of our interview with Don Tracy from @Pharmaceutical Executive, where we explain how our Femaseed technology supports women facing infertility challenges. https://lnkd.in/e8EYBehz #Femasys #Femaseed #infertility
Femasys Founder Discusses Femaseed Technology Designed to Support Infertility
pharmexec.com
To view or add a comment, sign in
-
NEW RESEARCH ALERT! Crystal Research Associates released a 48-page EIO on Evofem Biosciences, Inc. ($EVFM-OTCQB), a commercial-stage biopharmaceutical company focusing on women’s sexual and reproductive healthcare markets. Evofem's FDA-approved product, Phexxi®, is a hormone-free contraceptive vaginal gel, conveniently packaged in boxes with twelve pre-filled applicators. Inserted within one hour before intercourse, Phexxi maintains vaginal pH, reducing sperm motility and preventing pregnancy. Phexxi's non-systemic activity is crucial for the 23 million women unable to use hormone-based contraceptives due to side effects or drug interactions, including breastfeeding mothers, breast cancer patients/survivors, and those using GLP-1s for weight loss, who require additional birth control due to decreased effectiveness of oral contraceptive pills during certain times of the GLP-1 dosing regimen. Check out our report to learn more about the Company. #Evofem #EVFM #VaginalPhModulator #WomensHealthcare #WomensReproductiveHealthcare #Phexxi https://bit.ly/3QJz1ZH
To view or add a comment, sign in
-
NEW RESEARCH ALERT! Crystal Research Associates released a 48-page EIO on Evofem Biosciences, Inc. ($EVFM-OTCQB), a commercial-stage biopharmaceutical company focusing on women’s sexual and reproductive healthcare markets. Evofem's FDA-approved product, Phexxi®, is a hormone-free contraceptive vaginal gel, conveniently packaged in boxes with twelve pre-filled applicators. Inserted within one hour before intercourse, Phexxi maintains vaginal pH, reducing sperm motility and preventing pregnancy. Phexxi's non-systemic activity is crucial for the 23 million women unable to use hormone-based contraceptives due to side effects or drug interactions, including breastfeeding mothers, breast cancer patients/survivors, and those using GLP-1s for weight loss, who require additional birth control due to decreased effectiveness of oral contraceptive pills during certain times of the GLP-1 dosing regimen. Check out our report to learn more about the Company. #Evofem #EVFM #VaginalPhModulator #WomensHealthcare #WomensReproductiveHealthcare #Phexxi https://bit.ly/3QJz1ZH
To view or add a comment, sign in
-
🗣️‘Luteal phase support is a critical aspect of #fertility treatment that often does not receive the attention it deserves. Ensuring adequate levels of progesterone during this phase is crucial for the success of the treatment and to achieve #pregnancy’. Dr Juan Castillo M.D., Scientific Director of Instituto Bernabeu, participated this weekend in the Ferring Pharmaceuticals symposium held in Dublin under the theme ‘Updates in Human Reproduction: Challenges and Solutions’. Our colleague was one of the invited speakers at this important event, where he gave a presentation on optimal support strategies in the luteal phase of #assistedreproduction treatment. 🔗More informatión in the first comment of this post
To view or add a comment, sign in
-
We are excited to announce the publication of our new paper "Prevalence of Psychoactive Substance Use During Pregnancy in Argentine Women: A Pilot Study Testing Maternal Hair". The use of psychoactive substances during pregnancy is a major public health concern due to its increasing prevalence worldwide. For the first time in Argentina, it was examined the understudied issue of gestational psychoactive substance consumption on a cohort of delivering mothers. Our results highlighted the usefulness of maternal hair analysis not only to evidence gestational drugs use, but also the consumption habits during each half of pregnancy. 🔗 Check out our manuscript: https://lnkd.in/dcNqrp-E https://lnkd.in/dmP8cDpx This research has been possible thanks to the Research Group on Childhood and Environment (GRIE) of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), in collaboration with the Fundación para la Investigación Biomédica HULP (IdiPAZ) and the National Centre on Addiction and Doping of the Istituto Superiore di Sanità (ISS)! This work has been possible thanks to the joint effort of our researchers: Melina Vieiros Rodríguez, Afrooz Mirahi, Marina Villarreal, Anna Ramos Triguero, Iria Fernández-Rubal, Vicente Andreu Fernández, Simona Pichini, Oscar Garcia Algar and Emilia Marchei. Congratulations to the whole team for this achievement! 🎉🔬 #Research #Science #PsychoactiveSubstances #Pregnancy
Prevalence of Psychoactive Substance Use During Pregnancy... : Therapeutic Drug Monitoring
journals.lww.com
To view or add a comment, sign in
-
“Marijuana use during pregnancy linked to increase in childhood cancers, Duke study finds” 🪴 This is the Reefer Madness we’re still facing. Here’s what the study actually says, “Results: Respondents from 3145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%)…” The study says “illicit drugs including marijuana or cocaine (4%)”. The number and types of drugs isn’t specified, it just names two that are included. Since the total is 4%, what percentage of that 4% is marijuana ? 1%? Less than 1%? And how many were poly substance users? In addition, Causality vs. association: The study establishes associations but cannot definitively prove causation. Other factors beyond maternal substance use could contribute to these cancer developments. abc11.com/marijuana-preg…
To view or add a comment, sign in
-
When it comes to high-risk abortion drugs, the FDA hasn’t done its job. Since 2016, the FDA has scrapped nearly every safety measure—with no studies of the regimen it ultimately approved. The result? Women are now suffering the consequences of these high-risk drugs at home alone, without EVER seeing a doctor. • No gestational age check • No ectopic pregnancy screening • No doctor on call if something goes wrong And complications DO happen: from severe pain & emotional trauma to hemorrhage & sepsis. The FDA’s own label shows 1 in 25 women who take these drugs will end up in the ER. Women deserve better than this. They deserve informed consent when taking high-risk drugs. They deserve a doctor’s oversight. And they deserve an FDA that cares enough to do its job. Learn more about our groundbreaking case against the FDA: https://lnkd.in/esyQr2UW
To view or add a comment, sign in
-
Clinical Pharmacist /Collaborative Practice Agreement / Educator- Speaker/ MTM / Prior Authorizations/ Medical Writer/ Medicolegal Consulting- Expert Witness/ 5 Board certifications in Pharmacy
⚠ A multicenter observational cohort study involving over 9000 persons found that the composite adverse pregnancy outcome (small-for-gestational-age birth, medically indicated preterm birth, stillbirth, or hypertensive disorders of pregnancy) was more frequent in pregnant individuals with cannabis exposure ascertained by a urine drug assay (25.9%; n = 610) compared with unexposed individuals (17.4%; n = 8647). The risk for an adverse outcome was higher among those who continued to use cannabis beyond the first trimester. ⚠ Meaning Cannabis use should be avoided during pregnancy to optimize maternal and neonatal outcomes. https://lnkd.in/eD8DrqT7
Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function
jamanetwork.com
To view or add a comment, sign in
-
PHARMACISTS, take note, while Currently, the drug labels for GLP-1s do not include recommendations regarding birth control pills. There has not been a solid scientific study comparing Glp1 agonist patients on oral hormonal birth control to nonoral hormonal BC, like Nuva-ring. Best to use barrier protection if unsure. However, the FDA states that Mounjaro – a dual GIP/GLP-1 receptor agonist – may reduce the efficacy of oral birth control due to delayed gastric emptying. According to the drug label, Mounjaro is most likely to reduce birth control efficacy after the first dose, with this potential side effect diminishing over time. https://lnkd.in/es4pJp8x. https://lnkd.in/eDnxtXAj
'Ozempic babies' are surprising women taking weight loss drugs
dailymail.co.uk
To view or add a comment, sign in
7,373 followers